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Objective To determine if misoprostol is safe and efficacious in
preventing postpartum haemorrhage (PPH) when administered by
trained traditional birth attendants (TBA) at home deliveries.
Design A randomised, double-blind, placebo-controlled trial.
Setting Chitral, Khyber Pakhtunkhwa Province, Pakistan.
Population A total of 1119 women giving birth at home.
Methods From June 2006 to June 2008, consenting women were
randomised to receive 600 lg oral misoprostol (n = 534) or
placebo (n = 585) after delivery to determine whether misoprostol
reduced the incidence of PPH (‡500 ml).
Main outcome measures The primary outcomes were measured
blood loss ‡500 ml after delivery and drop in haemoglobin
>2 g/dl from before to after delivery.
Results Oral misoprostol was associated with a significant
reduction in the rate of PPH (‡500 ml) (16.5 versus 21.9%;
relative risk 0.76, 95% CI 0.59–0.97). There were no measurable
differences between study groups for drop in haemoglobin >2 g/dl
(relative risk 0.79, 95% CI 0.62–1.02); but significantly fewer
women receiving misoprostol had a drop in haemoglobin >3 g/dl,
compared with placebo (5.1 versus 9.6%; relative risk 0.53, 95%
CI 0.34–0.83). Shivering and chills were significantly more
common with misoprostol. There were no maternal deaths among
participants.
Conclusions Postpartum administration of 600 lg oral
misoprostol by trained TBAs at home deliveries reduces the rate
of PPH by 24%. Given its ease of use and low cost, misoprostol
could reduce the burden of PPH in community settings where
universal oxytocin prophylaxis is not feasible. Continual training
and skill-building for TBAs, along with monitoring and evaluation
of programme effectiveness, should accompany any widespread
introduction of this drug.
Trial registration http://clinicaltrials.gov/NCT00120237
Misoprostol for the Prevention of Postpartum Hemorrhage in
Rural Pakistan.
Keywords Misoprostol, postpartum haemorrhage, traditional birth
attendants.
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Introduction
Postpartum haemorrhage (PPH) continues to be the leading
single direct cause of maternal mortality worldwide.1 The
contribution of PPH to maternal death is disproportionately
higher in developing countries, particularly in rural settings
with limited infrastructure and availability of trained delivery
attendants and uterotonic agents for management of PPH.2,3
Despite global efforts to ensure that women deliver with
skilled birth attendants and have access to conventional
uterotonics for PPH prevention, 60% of births in low-
resource countries occur outside health facilities without a
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skilled attendant.4 In Pakistan, 65% of births occur at home
and 27% of maternal deaths are attributed to PPH.5
Active management of the third stage of labour (AMTSL)
is composed of immediate administration of a uterotonic,
controlled cord traction for placental delivery, and uterine
massage; and is internationally recognised as an evidence-
based intervention that reduces PPH caused by uterine
atony by up to 60%.6 The World Health Organization, as
well as other international agencies, recommends that
AMTSL be offered to all women delivering with a skilled
birth attendant.7–9 Published studies comparing the efficacy
and safety of various uterotonics confirm that oxytocin is
the preferred drug for AMTSL.10–12 However, it is not
always feasible to administer oxytocin in resource-poor set-
tings given its requirements for cool storage, sterile equip-
ment, skilled personnel and parenteral administration.13
Oxytocin prophylaxis is therefore mostly limited to facility-
based deliveries and to those attended by a skilled provider,
where the cold chain can be maintained, leaving the major-
ity of deliveries in community settings with no uterotonic
coverage.
Misoprostol, a prostaglandin E1 analogue that induces
strong uterine contractions, has been explored for prevent-
ing PPH in settings where injectable uterotonics are not yet
available or feasible to use. Three community-based rando-
mised controlled trials, where misoprostol was administered
at homebirths or at primary healthcare centres, have dem-
onstrated safe and effective use of misoprostol for PPH
prevention.14–16 A study in India confirmed that adminis-
tration of 600 lg oral misoprostol after delivery of the baby
significantly decreased the occurrence of PPH (‡500 ml)
(relative risk [RR] 0.53, 95% CI 0.39–0.74).16 A study in the
Gambia comparing oral misoprostol (600 lg) with standard
care (2 mg oral ergometrine) administered by trained tradi-
tional birth attendants (TBAs) at homebirths, showed a
nonsignificant trend in reduction of PPH with misoprostol,
and a statistically significant smaller drop in haemoglobin
(Hb) in the misoprostol arm.14 The third trial, testing a
600 lg regimen of sublingual misoprostol administered by
midwives in primary healthcare centres in Guinea-Bissau,
found that misoprostol was significantly better than placebo
in reducing severe PPH ‡ 1000 ml (11% misoprostol versus
17% placebo).15 A meta-analysis of the three trials shows a
statistically significant reduction in blood loss ‡1000 ml
(2% misoprostol versus 6% control).12
In 2007, the World Health Organization endorsed the
administration of oral misoprostol for PPH prevention by
unskilled providers ‘trained in its use in settings where
AMTSL is not practiced’ in its guidelines on prevention of
PPH.8 The Royal College of Obstetricians and Gynaecolo-
gists in its recent PPH guidelines also recommends use of
misoprostol when oxytocin is not available (for example, in
a homebirth).9 Given that only one published randomised
controlled trial has documented safe administration of
misoprostol for PPH prevention when administered
by trained TBAs in home delivery settings,14 there has
been a call for additional evidence to support expanding
misoprostol use for prevention of PPH in community set-
tings and by lower level providers.17 The current trial
sought to provide confirmatory evidence that 600 lg oral
misoprostol is effective in preventing PPH and to demon-
strate that TBAs can play the role of providers ‘trained in
its use’.
Methods
This double-blind randomised, placebo-controlled commu-
nity-based trial evaluated the efficacy and safety of 600 lg
oral misoprostol for the prevention of PPH in homebirth set-
tings. The trial sought to test whether misoprostol reduces
the incidence of PPH (‡500 ml) when administered by
trained TBAs during the third stage of labour. The study was
conducted in remote, mountainous villages of Chitral, Khy-
ber Pakhtunkhwa Province, Pakistan where approximately
half of all deliveries are conducted by an unskilled birth
attendant at home. In this setting, the villages are situated at
high elevations ranging from 1500 to 3500 m.
The TBAs, Lady Health Visitors (LHVs) and Community
Health Nurses (CHNs), who were part of the Aga Khan
Health Services, Pakistan (AKHS,P) network, were responsi-
ble for trial implementation. The study catchment area was
limited to 46 villages surrounding 17 primary healthcare cen-
tres located within a driving distance of 2 hours from
secondary-level facilities. Primary healthcare centres are
staffed by LHVs and CHNs and provide basic maternal and
child health services and obstetric care according to World
Health Organization guidelines.18 The LHVs working for the
AKHS,P centres have completed their matric grade ten in
addition to 2 years of training midwifery and community
health; CHNs have completed 3 years or more of training.
Both LHVs and CHNs are responsible for training and
supervision of TBAs and community health workers in the
area. AKHS,P staff provide training to TBAs, which includes
15 days of initial instruction on safe delivery practices and
referral procedures for women with complications. TBAs
also participate in 3-day refresher trainings annually. A key
component of their training is to keep centre-based staff
informed of any pregnant women in the area, or when home
delivery is imminent or has occurred.
Pregnant women in general good health, residing in one of
the 46 study villages, and planning to deliver at home with a
study TBA, were eligible for inclusion. Eligibility was con-
firmed by the LHV/CHN during antenatal care visit(s) and
informed consent was obtained in the local language with
signature or thumb impression. Iron folate tablets were given
to women to take at the earliest antenatal visit possible as
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standard of care. Women were not eligible if presenting with
pregnancy complications—such as hypertension, non-cepha-
lic presentation, polyhydramnios, previous caesarean section,
suspected multiple pregnancy, suspected still birth, antepar-
tum haemorrhage, and Hb <8 g/dl. These women were
referred for facility delivery. Eligible consenting women had
finger-prick blood samples taken for Hb assessment during
the last trimester of pregnancy, using a Hemocue handheld
device, which has a proven accuracy of ±1.5% compared
with the international reference method for testing Hb
(Hemocue, A¨ngelholm, Sweden). The Hemocue is a simple
means of collecting Hb measures at the community-level
where traditional laboratory techniques are not feasible.
Women not attending antenatal care were identified by study
TBAs and, if eligible, their consent was obtained and they
were enrolled at delivery.
Participating women had their home deliveries managed
by one of the 84 trained study TBAs. Immediately after
delivery of the baby and before placental delivery, women
were given by the study TBAs either three tablets of 200 lg
misoprostol (GyMiso; HRA Pharma, Paris, France) or
matching placebo (resembling misoprostol) to take orally.
Both women and TBAs were blinded to study assignment.
The use of a placebo was considered ethical because the
standard care for home deliveries with TBAs in the study
area is to give no prophylactic uterotonic at delivery. Study
medication was packed in numbered colour-coded boxes to
identify the randomisation sequence. Study TBAs were pro-
vided with specially designed colour-coded drug boxes
to ensure that the sequence was maintained. A computer-
generated random code in blocks of six was maintained by
Gynuity Health Projects in New York and not revealed
until data collection and cleaning were completed.
Providers were asked to document how the third stage
was managed for each participant. The TBAs are trained in
management of the third stage of labour, including per-
forming uterine massage, cord traction, delayed cutting of
the cord, and immediate suckling at the breast. To collect
postpartum blood loss, women were positioned on a peri-
neal sheet and bedpan for a minimum of 1 hour or until
active bleeding stopped—whichever occurred last. Study
TBAs were provided with a 1-hour timer to track that blood
was collected for 1 hour and were asked to estimate the
time in minutes between delivery of the baby and of the
placenta. Blood collected in the bedpan was transferred to a
measuring jar, which was then closed, and the used perineal
sheet and cotton roll were placed in a sealed plastic bag.
The closed measuring jar and sealed plastic bag were then
placed inside a plastic cooler which was tightly closed and
stored in a secure place in the woman’s home until the
LHV/CHN arrived for weighing, 1–2 days after delivery.
If any complications were experienced at the time of deliv-
ery, the study TBA followed standard procedures; including
performing uterine massage and arranging referral to a
higher level of care. Generally, referrals involved having a
skilled provider go to the woman’s home as opposed to
transferring her to the health facility.
When a delivery occurred, the community health worker
notified the facility-based staff, who then visited the woman
at home within 24–48 hours to weigh the blood collected
and interview the woman and TBA. At this visit, data were
collected on any adverse effects or problems occurring after
delivery. The LHV/CHN returned 3–5 days post-delivery to
measure the woman’s Hb.
Regular monitoring and training of study staff continued
throughout the duration of the trial. The LHVs/CHNs
conducted monthly follow-up visits with TBAs as part of
routine practice. Study procedures and practices for man-
aging deliveries were reviewed during these visits. The
LHVs/CHNs were also visited on a monthly basis by their
supervisors, at which time the study procedures were
reviewed to ensure protocol adherence. Refresher trainings
were held annually for all study staff.
The primary outcomes were PPH (defined as measured
blood loss ‡500 ml) and drop in Hb > 2 g/dl. Secondary
outcomes included intermediate and severe PPH (blood loss
‡750 and ‡1000 ml), mean blood loss and postpartum Hb
<9 and <11 g/dl. To detect a 35% difference in the propor-
tions of PPH (blood loss ‡500 ml) between the two study
arms, a sample size of 543 was needed for a power of 80%,
one-sided test and an alpha of 0.05 assuming that 15% of the
placebo group had PPH. Assuming that the proportion of
women experiencing a drop in Hb > 2 g/dl receiving placebo
would be 20%, 470 women were required for the same alpha
and power to detect a difference. The sample size was
increased to 700 per arm to allow for up to 25% of screened
women not delivering according to protocol. Characteristics
of the two study arms were compared using chi-square or
Fisher exact test for categorical variables and Mann–Whitney
U test for continuous variables. Analysis of outcomes by
year 1 and 2 was also conducted to explore whether
improved delivery practices and study implementation influ-
enced study outcomes. These subgroup analyses were not
defined a priori. Data were double entered in Epi Windows
(Centers for Disease Control, Atlanta, GA, USA) and later
transferred into spss (SPSS, Chicago, IL, USA) and sas (SAS
Institute Inc, Cary, NC, USA) for analysis. The protocol was
approved by the Ethical Review Committee at the Aga Khan
University (Karachi, Pakistan) and is reported in accordance
with the revised CONSORT statement (Figure 1).19
Results
During the initial 7 months of the study (25 October 2005
to 31 May 2006), 370 women were enrolled. A monitoring
visit in May 2006 confirmed difficulties in using the blood
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collection and measurement tools, inaccuracies in recorded
blood loss measures, and challenges with study monitoring
during the winter months. This period of recruitment was
therefore considered a pilot phase and all data collected
during the initial 7 months have been excluded from the
analysis. No safety issues were reported during the pilot
phase. During the subsequent 2 years of the study, 1119
women were randomised to receive either 600 lg misopr-
ostol orally (n = 534) or matching placebo (n = 585) dur-
ing the third stage of labour from June 2006 to June 2008.
In three deliveries, follow-up visits could not be carried
out; data analysis was therefore conducted for 1116 women
(misoprostol arm n = 533; placebo arm n = 583). With the
exception of median pre-delivery Hb levels, baseline and
delivery characteristics of women were similar (Table 1).
All women received study medication per protocol and all
outcomes were analysed by treatment assignment (per-pro-
tocol). Invalid blood loss measures, which mainly occurred
when monitoring visits were not possible because of
poor weather conditions, were excluded from our analysis
(Figure 1).
Data on blood loss after delivery were available for 514
women who received misoprostol and 558 who received
placebo. The primary outcome measure of blood loss
‡500 ml shows that women who received misoprostol had
a lower rate of PPH (16.5%) compared with 21.9% for
those given placebo (RR 0.76, 95% CI 0.59–0.97) (Table 2).
Median total blood loss after delivery was comparable
among the two study groups (P = 0.103). Ten women in
the misoprostol group had blood loss ‡1000 ml compared
with 19 women in the placebo group; however, this differ-
ence between arms did not reach statistical significance.
For every 19 women given misoprostol prophylactically,
one incidence of PPH (blood loss ‡500 ml) was averted.
Analysis of Hb exhibits a similar pattern of blood loss
(Table 2). A change in Hb levels >2 g/dl, pre- to post-deliv-
ery, was experienced by 16.7% of women given misoprostol,
compared with 21.0% in the placebo group (RR 0.79, 95%
CI 0.62–1.02). An analysis of drop in Hb > 3 g/dl shows that
Hb decreases were statistically different between study arms
(misoprostol 5.1% versus placebo 9.6%, RR 0.53, 95% CI
0.34–0.83). A smaller, yet clinically insignificant change in
Figure 1. CONSORT flow diagram: trial profile.
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Hb pre- to post-delivery was found in the misoprostol group,
with a median drop of 1.0 g/dl compared with 1.2 g/dl with
placebo (P = 0.016). Haemoglobin outcomes were also anal-
ysed for the subset of women who did not take iron folate
medication during pregnancy (misoprostol group = 78; pla-
cebo group = 98). Analyses of the change in Hb concentra-
tions pre- to post-delivery (>2 and >3 g/dl) confirmed that
findings were similar to those for the entire cohort (data not
shown).
Shivering and chills were the most commonly reported
adverse effects (Table 3); occurring for one of every ten
women receiving misoprostol and one of every 20 women
given placebo. Four cases of fever were detected in the
misoprostol group versus seven in the placebo group; and
all other adverse effects were minimal. There were no
maternal deaths or any other serious adverse events
reported during the trial. Retained placenta and PPH were
the most common reasons identified by the TBA for refer-
ral to higher level of care (Table 3). There were no differ-
ences between study groups in the proportion of women
receiving higher-level care (1.7% in misoprostol group
versus 1.7% in placebo group).
Figures 2 and 3 present the rates of PPH (‡500
and ‡1000 ml) and of Hb concentration changes (>2 and
>3 g/dl) over the course of the study. In the first year of the
study, the effect of misoprostol on PPH rates and changes in
Hb was negligible, whereas in the following year, misoprostol
was associated with a significant reduction in the rates of
PPH and in the proportion of women who experienced a
Hb drop >3 g/dl, compared with placebo (PPH: RR 0.69,
95% CI 0.49–0.99; severe PPH: RR 0.18, 95% CI 0.04–0.82;
Hb drop >3 g/dl: RR 0.38, 95% CI 0.18–0.80). Analysis of
the temporal trends within each study arm confirmed no
statistically significant reductions in rates of PPH or in Hb
changes in the placebo group. In the misoprostol group,
3.3% of women had severe PPH in the first year, compared
with 0.7% in the second year (RR 0.26, 95% CI 0.06–1.21).
Similar trends were observed for drops in Hb >2 and >3 g/dl
in the misoprostol group (respective RR 0.68, 95% CI 0.46–
1.00; RR 0.47, 95% CI 0.21–1.02).
Discussion
This randomised controlled trial shows that 600 lg oral
misoprostol confers benefit in the reduction of PPH among
women delivering at home with a trained TBA. Oral mi-
soprostol reduced the rate of PPH (‡500 ml) by 24% com-
pared with placebo. These findings corroborate published
evidence on the efficacy of misoprostol for PPH prevention
when used for home deliveries and in primary-care
centres.14–16 A placebo-controlled community-based trial
conducted in India showed a 50% reduction in
PPH ‡ 500 ml with misoprostol. The trial in India, as well
Table 1. Baseline and delivery characteristics by study group*
Misoprostol
n = 533
Placebo
n = 583
Age (years) mean (SD) 28 (5) 27 (4)
Parity
Para 1 103 (19.3) 117 (20.1)
Para 2 142 (26.7) 134 (23.0)
Para 3–5 226 (42.4) 270 (46.3)
Para 6 or more 62 (11.6) 62 (10.6)
Pre-delivery Hb**
Mean (SD) 12.7 (1.6) 12.9 (1.5)
Median (IQR)*** 12.8 (11.7, 13.7) 13.0 (12.0, 14.0)
Range 8.2–18.0 8.2–16.8
Pre-delivery Hb < 9 g/dl** 5 (0.9) 6 (1.0)
Pre-delivery Hb < 11
g/dl**
73 (13.8) 65 (11.3)
Number of ANC visits
median (IQR)
6 (4, 8) 6 (4, 8)
Iron folate tablets taken
during pregnancy
455 (85.4) 485 (83.3)
Number of months during
pregnancy for which iron
folate tablets were taken,
median (IQR)
3 (2, 4) 3 (2, 4)
Highest level of school
attended
(n = 531) (n = 580)
No formal education 386 (72.7) 397 (68.4)
Primary 53 (10.0) 79 (13.6)
Secondary and above 92 (17.3) 99 (17.0)
Woman’s occupation (multiple responses possible)
Housewife 527 (98.9) 573 (98.3)
Farmer 92 (17.3) 78 (13.4)
Professional 9 (1.7) 13 (2.2)
Delivery characteristics
Baby born alive 528 (99.1) 575 (98.6)
Nipple stimulation performed
by TBA at delivery
118 (22.1) 111 (19.0)
Uterine massage performed
by TBA at delivery
389 (73.0) 423 (72.6)
Cord traction performed by
TBA at delivery
151 (28.3) 168 (28.8)
Time (minutes) between
delivery of baby and
placenta as estimated by
TBAs, median (IQR)
20 (10, 30) 15 (10, 30)
Placental delivery within
30 minutes of delivery of
baby
368 (69.0) 418 (71.7)
IQR, interquartile range.
*Numbers are n (%) unless otherwise specified.
**Predelivery haemoglobin measures available for 528 women in
misoprostol group and 573 women in placebo group.
***Mann–Whitney U test confirms statistical significance with two-
tailed P-value of 0.043.
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as a trial conducted in Guinea Bissau, also documented
that misoprostol reduced the incidence of severe haemor-
rhage (‡1000 ml) by 80% and 34%, respectively.15,16
In comparison, the findings presented in this paper show a
statistically significant reduction in severe bleeding by 82%,
but only among women who delivered in the second year
of the study. Although misoprostol’s effect on blood loss
has largely been consistent across placebo-controlled trials
objectively measuring blood loss, differences in the magni-
tude of effect have been noted.11 Variation in delivery prac-
tices during the third stage of labour are postulated as
possibly contributing to these differences, as providers in
some trials practiced AMTSL whereas others practiced ‘pas-
sive’ management.11 Irrespective of these differences, this
trial strengthens the evidence base for justifying use of
misoprostol during routine third stage of labour management
when conventional injectable uterotonics are not feasible.
An unanticipated finding of this study relates to the
unusually high level of PPH documented in this popula-
tion, which averaged 19% among the study arms. In con-
trast with other community-based trials that compared
600 lg oral misoprostol with placebo or ergometrine, PPH
rates (‡500 ml) averaged 9 and 11%, respectively.14,16 High
blood loss outcomes in this setting may possibly be attrib-
uted to the high elevation and higher haemoglobin concen-
trations. Interestingly, a hospital-based study measuring
blood loss conducted in Llasa, Tibet (elevation 3650 m)
also documented a rate of PPH (‡500 ml) that averaged
15% between study arms comparing a similar misoprostol
regimen given prophylactically with a Tibetan traditional
medication administered during the third stage of labour.20
The present study also showed that significantly fewer
women in the misoprostol group experienced a drop in
Hb > 3 g/dl compared with women given placebo. This
finding concurs with previous research that exhibited a
protective effect of misoprostol on Hb levels when com-
pared with ergometrine or placebo.14,21,22 The clinical rele-
vance of misoprostol’s protective effect is critical, given
that PPH and anaemia contribute independently and inter-
actively to a large proportion of adverse maternal out-
comes. To this end, some guidelines note that pre- and
post-delivery Hb levels should be taken into consideration
when diagnosing cases of PPH and providing follow-up
care.9,23 In high elevation settings, where Hb concentrations
are notably higher, altitude-specific haemoglobin cut-offs
for defining iron deficiency deserve attention.24 This study
was designed to compare the proportions of women with
Hb levels <9 and <11 g/dl between study groups. However,
Table 2. Blood loss and haemoglobin (Hb) outcomes by study group*
Misoprostol Placebo Relative risk (95% CI)
Primary outcomes
Blood loss ‡500 ml** 85/514 (16.5) 122/558 (21.9) 0.76 (0.59–0.97)
Drop in Hb > 2 g/dl*** 88/528 (16.7) 120/572 (21.0) 0.79 (0.62–1.02)
Secondary outcomes
Blood loss (n = 514) (n = 558)
Blood loss ‡750 ml 29/514 (5.6) 40/558 (7.2) 0.79 (0.50–1.25)
Blood loss ‡1000 ml 10/514 (1.9) 19/558 (3.4) 0.57 (0.27–1.22)
Total blood loss (ml)
Median (IQR) 280 (200, 400) 300 (200, 460) –
Mean (SD) 337 (226) 366 (262)
Range 0–1820 20–1890
Haemoglobin (n = 533) (n = 581)
Post-delivery Hb
Median (IQR) 11.6 (10.5, 12.8) 11.6 (10.5, 12.8) –
Mean (SD) 11.6 (1.6) 11.5 (1.6)
Range (5.4–15.8) (5.0–16.0)
Post-delivery Hb < 9 g/dl 27/533 (5.1) 37/581 (6.4) 0.80 (0.49–1.29)
Post-delivery Hb < 11 g/dl 182/533 (34.1) 189/581 (32.5) 1.05 (0.89–1.24)
Change in Hb***
Median (IQR) 1.0 (0.5, 1.7) 1.2 (0.5, 1.9) –
Mean (SD) 1.1 (1.2) 1.3 (1.4)
Drop in Hb > 3 g/dl*** 27/528 (5.1) 55/572 (9.6) 0.53 (0.34–0.83)
*Numbers are n (%) unless otherwise specified.
**Blood measures available for 514 women in the misoprostol group and 558 women in the placebo group.
***Pre- and post-delivery Hb measures available for 528 women in the misoprostol group and 572 women in the placebo group for calculation
of change/drop in Hb levels from pre- to post-delivery.
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the number of women with Hb levels below these pre-spec-
ified cut-offs was quite low, and may not adequately reflect
iron deficiency in this population.
Shivering and fever are common adverse effects of
misoprostol; but adverse effects in this trial were relatively
low. Transient shivering and chills were experienced by
10% of women receiving misoprostol versus 5% in the pla-
cebo group. All other adverse effects, including fever, were
minimal, and their occurrence did not differ between study
arms. In previous PPH prevention studies, rates of shiver-
ing have been reported in as few as 19% of women follow-
ing 600 lg oral misoprostol, and as many as 62%.25
Isolated reports of transient fever above 40C have also
been documented in two trials testing a similar regimen
for PPH prevention.10,26 Previous reports of high fever
following a 600 lg regimen of oral misoprostol include five
of 9198 and four of 1026 women. None resulted in any
complication.10,26 The low rates of adverse effects docu-
mented in this study may be the result of recall bias by the
woman or TBA, as data collection on adverse effects did
not occur at the time of delivery but at the LHV’s follow-
up visit to the woman’s home 1–2 days postpartum. Body
temperature was not systematically measured after adminis-
tration of study medication.
The trial does have some limitations. Primarily, the out-
comes of this study may not be generalisable to all rural
settings. This trial was conducted in collaboration with
AKHS,P, capitalising on the extensive network between
AKHS,P providers and trained TBAs, with functioning
systems already in place for handling referrals. A second
limitation stems from the difficulties in validating blood
loss measurements during the initial phase of the study
when monitoring visits were not possible because of poor
weather conditions. The first external monitoring visit in
May 2006 revealed that the study team were incorrectly
using the blood assessment tools to collect, weigh and read
the scale and that additional training and more frequent
monitoring was needed. After a careful review of all data
collected to that point, the study team determined that
measures of blood collected from October 2005 through
May 2006 could not be analysed because they were invalid.
Nonetheless, the sample size was met by extending the
enrolment period. The exclusion of blood loss measures
during the first phase of the trial resulted in an under-
powered arm for analysing the primary outcome of PPH
(‡500 ml) and disproportionate samples for comparing
the two study groups. The difficulties that were encoun-
tered highlight the importance of conducting pilot studies
to ensure correct implementation of all study procedures.
A major strength of the trial is that rigorous data collec-
tion was ultimately possible in a remote setting, with TBAs
playing a major role in study implementation. Trained
Table 3. Adverse effects and referrals by study group*
Misoprostol
n = 533
Placebo
n = 583
P-value**
Adverse effects reported
Nausea 8 (1.5) 8 (1.4) 0.527
Vomiting 3 (0.6) 3 (0.5) 0.614
Diarrhoea 1 (0.2) 0 (0.0) 0.478
Shivering 50 (9.4) 23 (3.9) <0.0001
Chills/cold 53 (9.9) 29 (5.0) <0.0001
Fever 4 (0.8) 7 (1.2) 0.326
Headache 6 (1.1) 7 (1.2) 0.566
Weakness/fatigue 9 (1.7) 8 (1.4) 0.425
Dizziness/fainting 9 (1.7) 6 (1.0) 0.244
Referrals
Woman referred for higher level of care
Multiple reasons possible 9 (1.7) 10 (1.7) 0.579
Due to PPH 2 (0.4) 3 (0.5) 0.542
Due to retained placenta 7 (1.3) 7 (1.3) 0.538
Maternal death 0 (0.0) 0 (0.0) –
*Numbers are n (%) unless otherwise specified.
**One-tailed P-values are specified.
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Figure 2. Rates of PPH (‡500 and ‡1000 ml) for two sequential
subgroups of women randomised to receive misoprostol or placebo.
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Figure 3. Rates of Hb drop pre- to post-delivery (>2 and >3 g/dl) for
two sequential subgroups of women randomised to receive misoprostol
or placebo.
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TBAs, who were mostly illiterate, proved able to safely and
correctly follow instructions regarding the administration
of misoprostol after delivery of the baby, collect blood loss,
and manage referrals in a timely manner. With adequate
training and supervision provided by AKHS,P, there were
no safety issues in this study, and TBAs were able to recog-
nise and arrange prompt referrals for complications of
delivery. The temporal trends in Figures 2 and 3 under-
score the importance of continual support, training, and
skill-building. In the second year of the study, misoprostol
was associated with significant reduction in postpartum
bleeding and in the proportion of women who experienced
clinically important changes in haemoglobin concentra-
tions; whereas the first year did not produce any measur-
able differences between the two study arms. These trends
suggest that other factors besides uterotonic potency, such
as improved implementation, training and delivery skills,
may have contributed to misoprostol’s measurable effect
on PPH prevention in the second year of the study. In fact,
an analysis of other outcome variables shows significant
improvements in both antenatal and delivery care in the
last year of the study, in comparison with the first year
(data not shown).
Based on a 2006 technical consultation on the prevention
of PPH, the World Health Organization recommends that in
the absence of AMTSL uterotonic drugs be offered by health
workers trained in their use.8 In this document, the WHO
notes ‘‘For misoprostol, this recommendation places a high
value on the benefits of avoiding PPH and the ease of admin-
istration of an oral drug in settings in which other care is not
available.’’8 This study adds to the evidence that misoprostol
can be administered safely by trained TBAs and is effective in
reducing PPH when other active management components
are practiced.14 Homebirth remains the strong preference,
and often the only option, for many women in the develop-
ing world. A large proportion of these births take place with-
out skilled birth attendants: the total number is estimated at
60 million annually. To train the 400 000 midwives needed
to cover these deliveries, as well as finding the required sala-
ries, housing and allowances for postings in rural areas, work
opportunities for their spouses and educational facilities for
their children, will take time.27 Misoprostol administration
by health workers trained in its use for the prevention of
PPH can have immediate benefits.
There are some unanswered questions related to misopr-
ostol use for PPH prevention. For instance, current evidence
supports a 600 lg oral dose, yet it is conceivable that 400 lg
could also be effective. A recent meta-analysis found no ben-
efit of 600 over 400 lg misoprostol for blood loss ‡1000 ml
(RR 1.02, 95% CI 0.71–1.48).28 A lower dose may decrease
the adverse effects experienced associated with misoprostol.
As more evidence becomes available on lower doses of
misoprostol for PPH prevention, dosage recommendations
should be re-evaluated. Additional research may also be
needed to document the effectiveness of large service delivery
programmes offering misoprostol for PPH prevention and to
better understand whether postpartum misoprostol adminis-
tration will save lives. Furthermore, to achieve the United
Nation’s Millennium Development Goal #5 to improve
maternal health, urgent action and investment are needed to
accelerate progress for coverage of clinical-care interventions,
which depend on adequate access, human resources and
essential supplies.29
These findings provide additional evidence for the role
of misoprostol in reducing PPH when administered by a
trained TBA. Given that, for now, misoprostol may be the
only feasible PPH prevention option, it should be endorsed
as a safe and effective alternative intervention for use at
home deliveries.
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